Abstracts tagged "treatment guidlelines and treatment options"

Abstract Number: 2488 • 2018 ACR/ARHP Annual Meeting
Characteristics of Difficult-to-Treat Rheumatoid Arthritis: Results of an International Survey
Nadia MT Roodenrijs¹, Maria JH de Hair¹, Marlies C van der Goes¹, Johannes W. G. Jacobs¹, Paco MJ Welsing¹, Désirée van der Heijde², Daniel Aletaha³, Maxime Dougados⁴, Kimme L. Hyrich⁵, Iain B. McInnes⁶, Ulf Müller-Ladner⁷, Ladislav Šenolt⁸, Zoltan Szekanecz⁹, Jacob van Laar¹ and Gyorgy Nagy¹⁰, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Department of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris Descartes University, Paris, France, Paris, France, ⁵Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁶Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK, Glasgow, United Kingdom, ⁷Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, ⁸First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁹Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, Debrecen, Hungary, ¹⁰Department of Genetics, Cell- and Immunobiology & Department of Rheumatology, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary, Budapest, Hungary
Background/Purpose: EULAR and ACR recommendations on the management of rheumatoid arthritis (RA) mainly focus on early RA and medication.1,2 Following these recommendations, several patients nevertheless…
Abstract Number: 1342 • 2017 ACR/ARHP Annual Meeting
Comprehensive Provider Judgment Outweighs Disease Activity Measures in the Decision to Not Escalate Therapy in Patients with Moderate to Severe Rheumatoid Arthritis
Jacob R. Stever¹, Brian Sauer², Chia-Chen Teng, MS¹, Neil Accortt³, David Collier⁴ and Grant Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., Thousand Oaks, CA
Title: Comprehensive provider judgment outweighs disease activity measures in the decision to not escalate therapy in patients with moderate to severe rheumatoid arthritis. Authors: Stever,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].